211 related articles for article (PubMed ID: 21358674)
21. BRN2, a POUerful driver of melanoma phenotype switching and metastasis.
Fane ME; Chhabra Y; Smith AG; Sturm RA
Pigment Cell Melanoma Res; 2019 Jan; 32(1):9-24. PubMed ID: 29781575
[TBL] [Abstract][Full Text] [Related]
22. GLI2 and M-MITF transcription factors control exclusive gene expression programs and inversely regulate invasion in human melanoma cells.
Javelaud D; Alexaki VI; Pierrat MJ; Hoek KS; Dennler S; Van Kempen L; Bertolotto C; Ballotti R; Saule S; Delmas V; Mauviel A
Pigment Cell Melanoma Res; 2011 Oct; 24(5):932-43. PubMed ID: 21801332
[TBL] [Abstract][Full Text] [Related]
23. BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma.
Herbert K; Binet R; Lambert JP; Louphrasitthiphol P; Kalkavan H; Sesma-Sanz L; Robles-Espinoza CD; Sarkar S; Suer E; Andrews S; Chauhan J; Roberts ND; Middleton MR; Gingras AC; Masson JY; Larue L; Falletta P; Goding CR
Genes Dev; 2019 Mar; 33(5-6):310-332. PubMed ID: 30804224
[TBL] [Abstract][Full Text] [Related]
24. Negative Regulatory Loop between Microphthalmia-Associated Transcription Factor (MITF) and Notch Signaling.
Golan T; Levy C
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30699982
[TBL] [Abstract][Full Text] [Related]
25. STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pathway.
Swoboda A; Soukup R; Eckel O; Kinslechner K; Wingelhofer B; Schörghofer D; Sternberg C; Pham HTT; Vallianou M; Horvath J; Stoiber D; Kenner L; Larue L; Poli V; Beermann F; Yokota T; Kubicek S; Krausgruber T; Rendeiro AF; Bock C; Zenz R; Kovacic B; Aberger F; Hengstschläger M; Petzelbauer P; Mikula M; Moriggl R
Oncogene; 2021 Feb; 40(6):1091-1105. PubMed ID: 33323974
[TBL] [Abstract][Full Text] [Related]
26. Phenotypic diversity of patient-derived melanoma populations in stem cell medium.
Sztiller-Sikorska M; Hartman ML; Talar B; Jakubowska J; Zalesna I; Czyz M
Lab Invest; 2015 Jun; 95(6):672-83. PubMed ID: 25867763
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
Kundu A; Quirit JG; Khouri MG; Firestone GL
Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
[TBL] [Abstract][Full Text] [Related]
28. Hypoxia and MITF regulate KIT oncogenic properties in melanocytes.
Laugier F; Delyon J; André J; Bensussan A; Dumaz N
Oncogene; 2016 Sep; 35(38):5070-7. PubMed ID: 26973244
[TBL] [Abstract][Full Text] [Related]
29. Co-expression of SOX9 and SOX10 during melanocytic differentiation in vitro.
Cook AL; Smith AG; Smit DJ; Leonard JH; Sturm RA
Exp Cell Res; 2005 Aug; 308(1):222-35. PubMed ID: 15896776
[TBL] [Abstract][Full Text] [Related]
30.
Ennen M; Keime C; Gambi G; Kieny A; Coassolo S; Thibault-Carpentier C; Margerin-Schaller F; Davidson G; Vagne C; Lipsker D; Davidson I
Clin Cancer Res; 2017 Nov; 23(22):7097-7107. PubMed ID: 28855355
[No Abstract] [Full Text] [Related]
31. Expression of genes for microphthalmia isoforms, Pax3 and MSG1, in human melanomas.
Vachtenheim J; Novotná H
Cell Mol Biol (Noisy-le-grand); 1999 Nov; 45(7):1075-82. PubMed ID: 10644012
[TBL] [Abstract][Full Text] [Related]
32. Peptide R18H from BRN2 Transcription Factor POU Domain Displays Antitumor Activity In Vitro and In Vivo and Induces Apoptosis in B16F10-Nex2 Cells.
da Cunha FFM; Mugnol KCU; de Melo FM; Nascimento MVSQ; de Azevedo RA; Santos RTS; Magalhães JA; Miguel DC; Tada DB; Mortara RA; Travassos LR; Arruda DC
Anticancer Agents Med Chem; 2019; 19(3):389-401. PubMed ID: 30417795
[TBL] [Abstract][Full Text] [Related]
33. PPAR gamma regulates MITF and beta-catenin expression and promotes a differentiated phenotype in mouse melanoma S91.
Grabacka M; Placha W; Urbanska K; Laidler P; Płonka PM; Reiss K
Pigment Cell Melanoma Res; 2008 Jun; 21(3):388-96. PubMed ID: 18444964
[TBL] [Abstract][Full Text] [Related]
34. Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny.
Cheli Y; Giuliano S; Botton T; Rocchi S; Hofman V; Hofman P; Bahadoran P; Bertolotto C; Ballotti R
Oncogene; 2011 May; 30(20):2307-18. PubMed ID: 21278797
[TBL] [Abstract][Full Text] [Related]
35. MITF in melanoma: mechanisms behind its expression and activity.
Hartman ML; Czyz M
Cell Mol Life Sci; 2015 Apr; 72(7):1249-60. PubMed ID: 25433395
[TBL] [Abstract][Full Text] [Related]
36. MITF, the Janus transcription factor of melanoma.
Koludrovic D; Davidson I
Future Oncol; 2013 Feb; 9(2):235-44. PubMed ID: 23414473
[TBL] [Abstract][Full Text] [Related]
37. Isolation and characterization of spheroid cells from human malignant melanoma cell line WM-266-4.
Na YR; Seok SH; Kim DJ; Han JH; Kim TH; Jung H; Lee BH; Park JH
Tumour Biol; 2009; 30(5-6):300-9. PubMed ID: 19940551
[TBL] [Abstract][Full Text] [Related]
38. Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP.
Wang R; He Y; Robinson V; Yang Z; Hessler P; Lasko LM; Lu X; Bhathena A; Lai A; Uziel T; Lam LT
Mol Cancer Ther; 2018 Dec; 17(12):2543-2550. PubMed ID: 30266801
[TBL] [Abstract][Full Text] [Related]
39. microRNA-155, induced by interleukin-1ß, represses the expression of microphthalmia-associated transcription factor (MITF-M) in melanoma cells.
Arts N; Cané S; Hennequart M; Lamy J; Bommer G; Van den Eynde B; De Plaen E
PLoS One; 2015; 10(4):e0122517. PubMed ID: 25853464
[TBL] [Abstract][Full Text] [Related]
40. Heterogeneous SWI/SNF chromatin remodeling complexes promote expression of microphthalmia-associated transcription factor target genes in melanoma.
Keenen B; Qi H; Saladi SV; Yeung M; de la Serna IL
Oncogene; 2010 Jan; 29(1):81-92. PubMed ID: 19784067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
